Article
Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.
BioMed research international - 1 Jan 2021
Lv Fangfang, Sun Liang, Yang Qiuping, Pan Zheng, Zhang Yuhua
Abstract excerpt
BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients. A germline 2903 bp deletion polymorphism of Bcl-2-like protein 11 (BIM) causes reduced expression of proapoptotic BH3-only BIM protein and blocks TKI-induced apoptosis of tumor cells. Yet the association between the deletion polymorphism and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
